This achievement underscores Uzbekistan's commitment to strengthening global safety and quality standards for pharmaceutical products.

Membership in the IPRP provides Uzbekistan with a unique opportunity to cooperate and share experience with leading global regulators, including the FDA (USA), EMA (European Union), PMDA (Japan), MHRA (UK), Health Canada (Canada), ANVISA (Brazil) and other agencies from more than 30 countries. IPRP also unites regional and international organizations, contributing to the harmonization of requirements for the safety, effectiveness and quality of medicines.

At a recent meeting of the IPRP Management Committee in Montreal, the director of the Center, Alisher Temirov, presented Uzbekistan's achievements in the field of pharmaceutical regulation, eliciting positive responses. As a result of the discussion, it was unanimously decided to assign Uzbekistan the status of a full member.

Membership in the IPRP will allow Uzbekistan not only to adopt best practices, but also to actively participate in the development of unified approaches to regulation, which is especially important in the context of growing global interdependence in the pharmaceutical industry.

This step opens up new prospects for the harmonization of national standards with international requirements, as well as for further strengthening Uzbekistan's position on the world stage of the pharmaceutical industry.